Michael Lobritz is the Head of Infectious Diseases Early Development at F. Hoffmann-La Roche, Ltd, based in Basel, Switzerland. His group is responsible for the translational development of Roche antibiotics and antivirals from Phase 0 through Phase 2, including the demonstration of proof-of-mechanism and proof-of concept. Prior to joining Roche in 2017, Michael was attending physician in medicine and infectious diseases at Massachusetts General Hospital and Instructor in Medicine at Harvard Medical School, both in Boston, USA. Michael previously completed postdoctoral research simultaneously at the Broad Institute of MIT and Harvard and at the Wyss Institute of Biologically Inspired Engineering at Harvard University, infectious diseases clinical training at Massachusetts General Hospital, clinical medicine training at Stanford University Hospital, MD and PhD (microbiology) degrees at Case Western Reserve University, and undergraduate degree (biochemistry) at the University of Notre Dame.